Bioventix PLC (GB:BVXP)

LSE:BVXP

BVXP

Bioventix

RESEARCH TOOLSreports

Want to see GB:BVXP full AI Analyst Report?

Bioventix (BVXP) Price & Analysis

16 Followers

BVXP Stock Chart & Stats

1800.00 p

56.00 p(1.70%)

At close: Jan 09 4:00 PM EST

1800.00 p

56.00 p(1.70%)

Day’s Range― - ―

52-Week Range1,300.00 p - 3,020.00 p

Previous CloseN/A

Volume24.00

Average Volume (3M)7.85K

Market Cap

£88.82M

Enterprise Value83.52M

Total Cash (Recent Filing)£5.30M

Total Debt (Recent Filing)£0.00

Price to Earnings (P/E)6.9

Beta0.67

Next Earnings

Nov 02, 2026

EPS Estimate

0.66

Next Dividend Ex-DateN/A

Dividend Yield8.33%

Share Statistics

EPS (TTM)0.68

Shares Outstanding5,224,860

10 Day Avg. Volume9,152

30 Day Avg. Volume7,851

Financial Highlights & Ratios

PEG Ratio-2.93

Price to Book (P/B)12.43

Price to Sales (P/S)10.95

P/FCF Ratio20.47

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)1.36

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

High Margins & ProfitabilitySustained very high gross and net margins indicate durable pricing power and differentiated antibody performance. High profitability supports long-term cash generation, funds R&D or payouts, and cushions the business against volume shocks given recurring royalty and reagent revenue streams.

Zero Debt & Strong ROEA debt-free balance sheet and extremely high ROE materially reduce financial risk and provide flexibility for capital allocation. This structural strength supports consistent dividend policy or reinvestment and helps the firm weather cyclical diagnostic demand downturns.

High Cash ConversionNearly one-to-one conversion of earnings into free cash flow signals high-quality earnings and predictable internal funding. Reliable FCF underpins sustainable dividends, selective R&D or capacity investments, and lowers reliance on external financing over multi-quarter horizons.

Bears Say

Revenue & FCF SlowdownA multi-year leader with recent 2025 declines in revenue and FCF faces a material inflection risk: if underlying demand or product placements weaken, reinvestment and payout capacity may be constrained and growth optionality narrowed for several quarters.

Customer/contract ConcentrationRevenue dependence on a limited set of diagnostic OEM customers and opaque contract terms creates persistent counterparty risk. Loss or repricing of a major commercial partner can materially reduce royalties and reagent sales over the medium term.

Smaller Scale & Shrinking Equity BaseA compact operating base and a declining equity/asset base limit scalability and investment firepower. With few employees and shrinking balance-sheet scale, expanding commercial footprint or rapidly supporting new large OEM programs could be more challenging over coming quarters.

Bioventix News

Bioventix Ties Executive Share Options to Neurological Test Revenue Milestone

Bioventix ( ($GB:BVXP) ) just unveiled an update. Bioventix plc has granted share options to chief executive Peter...

7d ago

Bioventix Chairman Increases Stake with Share Purchase

Bioventix ( ($GB:BVXP) ) just unveiled an update. Bioventix has announced that its non-executive chairman, Ian Nicholson, has...

14d ago

Bioventix CEO Increases Stake After Share Purchases with Spouse

Bioventix ( ($GB:BVXP) ) has issued an announcement. Bioventix has disclosed that chief executive Peter Harrison and his...

19d ago

Bioventix CFO Increases Personal Stake with Share Purchase

Bioventix ( ($GB:BVXP) ) has shared an update. Bioventix plc reported that its Chief Financial Officer, Bruce Hiscock,...

25d ago

Bioventix Leans on Neuro Antibodies as Interim Profits Hold Steady

Bioventix ( ($GB:BVXP) ) just unveiled an announcement. Bioventix reported a modest dip in interim revenue to £6.16m...

28d ago

Bioventix strengthens board with appointment of diagnostics veteran Chris Yates

The latest update is out from Bioventix ( ($GB:BVXP) ). Bioventix plc, the AIM-listed UK antibody developer and...

2M ago

Bioventix CFO Increases Stake with Share Purchase

Bioventix ( ($GB:BVXP) ) has shared an update. Bioventix plc announced that its Chief Financial Officer, Bruce Hiscock,...

5M ago

Bioventix Posts Annual Report and Announces AGM

The latest announcement is out from Bioventix ( ($GB:BVXP) ). Bioventix plc has announced the posting of its...

6M ago

Bioventix CEO Increases Stake in Company

The latest update is out from Bioventix ( ($GB:BVXP) ). Bioventix plc announced that its CEO, Peter Harrison,...

6M ago

Bioventix Chairman Increases Stake in Company

An announcement from Bioventix ( ($GB:BVXP) ) is now available. Bioventix plc announced that Ian Nicholson, the Non-Executive...

6M ago

BVXP FAQ

What was Bioventix PLC’s price range in the past 12 months?

Bioventix PLC lowest share price was 1300.00 p and its highest was 3020.00 p in the past 12 months.

What is Bioventix PLC’s market cap?

Bioventix PLC’s market cap is £88.82M.

When is Bioventix PLC’s upcoming earnings report date?

Bioventix PLC’s upcoming earnings report date is Nov 02, 2026 which is in 189 days.

How were Bioventix PLC’s earnings last quarter?

Bioventix PLC released its earnings results on Mar 30, 2026. The company reported 0.684 p earnings per share for the quarter, beating the consensus estimate of 0.51 p by 0.174 p.

Is Bioventix PLC overvalued?

According to Wall Street analysts Bioventix PLC’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Bioventix PLC pay dividends?

Bioventix PLC pays a Semiannually dividend of 80 p which represents an annual dividend yield of 8.33%. See more information on Bioventix PLC dividends here

What is Bioventix PLC’s EPS estimate?

Bioventix PLC’s EPS estimate is 0.66.

How many shares outstanding does Bioventix PLC have?

Bioventix PLC has 5,224,860 shares outstanding.

What happened to Bioventix PLC’s price movement after its last earnings report?

Bioventix PLC reported an EPS of 0.684 p in its last earnings report, beating expectations of 0.51 p. Following the earnings report the stock price went up 6.909%.

Which hedge fund is a major shareholder of Bioventix PLC?

Currently, no hedge funds are holding shares in GB:BVXP

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Bioventix Stock Smart Score

Neutral

Fundamentals

Return on Equity

65.83%

Trailing 12-Months

Asset Growth

0.19%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Bioventix PLC

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in London, the United Kingdom.